Skip to main content
SpringerLink
Log in

Better Analysis for Better Decisions: Has Pharmacoeconomics Come of Age?

  • Editorial
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Better analysis for better decisions: a conference in honour of Bernie O’Brien; 2006 June 19–20. Further details on this conference can be found at http://www.path-hta.ca/bernie.htm.

References

  1. Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions: so much for guidelines. Pharmacoeconomics 2000; 18 (1): 55–62

    Article  PubMed  CAS  Google Scholar 

  2. Hill SR, Mitchell AS, Henry D. Problems with the interpretation of pharmacoeconomic analyses: a review of submission to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283 (16): 2116–21

    Article  PubMed  CAS  Google Scholar 

  3. Weinstein MC, Toy EL, Samberg EA, et al. Modeling for health care and other policy decisions: uses, roles and validity. Value Health 2001; 4: 348–61

    Article  PubMed  CAS  Google Scholar 

  4. Phillips Z, Ginnelly L, Sculpher M, et al. A review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36): 1–158

    Google Scholar 

  5. Nord E, Pinto JL, Richardson J, et al. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ 1999; 8: 25–39

    Article  PubMed  CAS  Google Scholar 

  6. Williams AH. Intergenerational equity: an exploration of the ‘fair innings’ argument. Health Econ 1997; 6: 117–32

    Article  PubMed  CAS  Google Scholar 

  7. Manca A, Rice N, Sculpher MJ, et al. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 2005; 14: 471–85

    Article  PubMed  Google Scholar 

  8. Grieve R, Nixon R, Thompson S, et al. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ 2005; 14: 185–96

    Article  PubMed  Google Scholar 

  9. Willan AR, Pinto EM, O’Brien BJ, et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT — 3 economic analysis. Health Econ 2005; 14: 327–38

    Article  PubMed  Google Scholar 

  10. Barbieri M, Drummond MF, Wilke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005; 8: 10–23

    Article  PubMed  Google Scholar 

  11. Ades AE, Sculpher MJ, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24 (1): 1–19

    Article  PubMed  CAS  Google Scholar 

  12. Sculpher MJ, Claxton KP. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty: when is there sufficient evidence? Value Health 2005; 8: 433–46

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this editorial. The authors have no conflicts of interest that are directly relevant to the content of this editorial.

Author information

Authors and Affiliations

  1. Centre for Health Economics, University of York, Heslington, York, YO10 5DD, England

    Michael Drummond & Mark Sculpher

Authors
  1. Michael Drummond
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Sculpher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Sculpher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drummond, M., Sculpher, M. Better Analysis for Better Decisions: Has Pharmacoeconomics Come of Age?. Pharmacoeconomics 24, 107–108 (2006). https://doi.org/10.2165/00019053-200624020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200624020-00001

Search

Navigation